A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant natural killer T cells, or NKT cells—powerful immune cells with a unique ability to infiltrate solid tumors—and systematically compared four targeting systems, called chimeric antigen receptors, or CARs, that direct these cells to attack cancer.
This article was originally published on MedicalXpress.com
